Navigate BioPharma Services has launched a new assay to measure and quantify the impact of radioligand therapies on tumor markers. The development of the assay was presented at the American Association for Cancer Research (AACR) 2024 Annual Meeting in California.

The assay is designed to measure changes in cancerous cells and tissue post-radioligand therapy using multiplex immunofluorescence (mIF) and automated quantitative analysis (AQUA) algorithms to precisely calculate variations in key protein markers within tumor tissues. The key features of the product include multiplex analysis, AQUA algorithms, and high sensitivity to subtle changes in protein levels. 

Navigate BioPharma Services, a subsidiary of Novartis, offers specialty laboratory services, including biomarker, bioanalytical, and diagnostic support services and clinical trial services. The company’s services span multiple therapeutic areas, including oncology, hematology, neurology, and rare diseases. Navigate BioPharma focuses on developing new biomarker solutions and custom validations to support drug development from discovery phases to clinical trials.